Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Other Non-Current Liabilities (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Other Non-Current Liabilities for 13 consecutive years, with $52.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities rose 62.47% year-over-year to $52.4 million, compared with a TTM value of $52.4 million through Sep 2025, up 62.47%, and an annual FY2024 reading of $32.4 million, up 1.69% over the prior year.
  • Other Non-Current Liabilities was $52.4 million for Q3 2025 at Tandem Diabetes Care, up from $52.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $52.4 million in Q3 2025 and bottomed at $116000.0 in Q3 2021.
  • Average Other Non-Current Liabilities over 5 years is $27.2 million, with a median of $26.6 million recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities crashed 99.33% in 2021, then skyrocketed 19752.59% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $17.8 million in 2021, then surged by 34.07% to $23.9 million in 2022, then soared by 33.08% to $31.8 million in 2023, then rose by 1.69% to $32.4 million in 2024, then surged by 61.82% to $52.4 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for TNDM at $52.4 million in Q3 2025, $52.1 million in Q2 2025, and $37.1 million in Q1 2025.